- Research article
- Open Access
Harmful and potentially harmful constituents (HPHCs) in two novel nicotine pouch products in comparison with regular smokeless tobacco products and pharmaceutical nicotine replacement therapy products (NRTs)
BMC Chemistry volume 17, Article number: 9 (2023)
Tobacco-free nicotine pouches is a novel category of oral nicotine-delivery products. Among current tobacco users such pouches may serve as a low-risk alternative to cigarettes or conventional, tobacco-based oral products e.g., snus and moist snuff. In the United States (U.S.), the market leading nicotine-pouch brand is ZYN®. However, no data on the chemical characteristics of ZYN have been published.
We screened for 43 compounds potentially present in tobacco products in seven oral nicotine-delivery products: ZYN (dry and moist), snus (General®), moist snuff (CRP2.1 and Grizzly Pouches Wintergreen), and two pharmaceutical, nicotine replacement therapy products (NRTs, Nicorette® lozenge and Nicotinell® gum). Thirty-six of the tested compounds are classified as harmful and potentially harmful constituents (HPHCs) by the Center for Tobacco Products at the U.S. Food and Drug Administration (FDA-CTP). Five additional compounds were included to cover the GOTHIATEK® product standard for Swedish snus and the last two compounds were chosen to include the four primary tobacco specific nitrosamines (TSNAs).
The tested products contained nicotine at varying levels. The two ZYN products contained no nitrosamines or polycyclic aromatic hydrocarbons (PAHs) but low levels of ammonia, chromium, formaldehyde, and nickel. In the NRT products we quantified low levels of acetaldehyde, ammonia, cadmium, chromium, lead, nickel, uranium-235, and uranium-238. The largest number (27) and generally the highest levels of HPHCs were quantified in the moist snuff products. For example, they contained six out of seven tested PAHs, and seven out of ten nitrosamines (including NNN and NNK). A total of 19 compounds, none of which were PAHs, were quantified at low levels in the snus product. NNN and NNK levels were five to 12-fold lower in snus compared to the moist snuff products.
No nitrosamines or PAHs were quantified in the ZYN and NRT products. Overall, the number of quantified HPHCs were similar between ZYN and NRT products and found at low levels.
Long-term epidemiological studies have convincingly shown that use of traditional, tobacco-based Swedish snus is associated with substantially fewer and/or less severe adverse health effects than cigarette smoking . In Sweden, snus has since the early 1970s to a large extent replaced cigarettes, particularly among male tobacco users and is now the dominating tobacco product on the Swedish market [2, 3]. The extensive use of snus instead of cigarettes has contributed to internationally record low rates of smoking and smoking-and tobacco-related disease, a phenomenon often referred to as the “Swedish Experience” in the literature. According to the World Health Organization (WHO) Swedish males have the European Union’s lowest rate of “tobacco-related” mortality .
In 2019, eight snus products marketed in the United States (U.S.) were granted a modified risk tobacco product (MRTP) order by the U.S. Food and Drug Administration’s Center for Tobacco Products (FDA-CTP) . The scientific basis for the MRTP order came in part from the “Swedish Experience” . Furthermore, the snus products are manufactured according to a stringent product standard (GOTHIATEK®) which includes maximum levels for several constituents classified as harmful and potentially harmful (HPHC) by the FDA .
From its launch in 2000, GOTHIATEK covered tobacco specific nitrosamines (TSNAs) (most notably N-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)), and polycyclic aromatic hydrocarbons (PAHs) (including benzo[a]pyrene (B(a)P)). From a long-term health point of view, NNN, NNK, and B(a)P have historically been regarded as the most problematic HPHCs in snus. Although the GOTHIATEK maximum levels have been gradually lowered over the years, and despite improved manufacturing methods snus products still contain measurable levels of NNN and NNK. However, discontinued use of fire-cured tobacco has led to over 95% lower levels of B(a)P in snus [2, 7]. Moreover, the levels of NNN, NNK and B(a)P are substantially lower in snus than in moist snuff products [8, 9].
In recent years several pouched, nicotine delivery products intended for oral use that do not contain tobacco (in the following referred to as “nicotine pouches”) have become commercially available in Europe and the U.S. A nicotine pouch is used in the same way as snus: it is placed under the upper lip where it delivers nicotine systemically via the oral mucosa. After use, the pouch is discarded. In the U.S., the market leader in this novel category is a product sold under the brand name ZYN® which in 2019 had a market share of 86% . As nicotine pouches do not contain tobacco and the added nicotine has a purity that meets pharmaceutical standards they should, at least in theory, not expose users to the HPHCs that are typically present in tobacco, such as TSNAs.
This paper presents the results of a screening for 43 selected compounds in two nicotine pouch products, ZYN dry and ZYN moist. For comparative purposes, the screening was also performed in one pouched Swedish snus product, two types of moist snuff (loose and pouched), and two pharmaceutical nicotine replacement therapy products (NRTs, lozenge and gum).
Material and methods
Table 1 summarizes selected characteristics of the tested products.
ZYN nicotine pouches
Two variants of ZYN were tested: ZYN dry which has a 3% moisture content and comes in a rectangular pouch made of a non-woven material. The pouch measures 14 × 28 mm and weighs 0.4 g. The pouch contains fillers (maltitol and microcrystalline cellulose), a stabilizer (hydroxypropyl cellulose), pH adjusters (sodium carbonate and sodium bicarbonate), a nicotine salt, food grade flavorings, and a sweetener (acesulfame K).
ZYN moist which has a 37% moisture content and comes in a rectangular pouch made of a non-woven material. The pouch measures 13.5 × 34 mm and weighs 0.8 g. The pouch ingredients are slightly different from that of ZYN dry: water, fillers (microcrystalline cellulose and plant fibers), a humectant (glycerine), pH adjusters (sodium carbonate and calcium chloride), sodium chloride, food grade flavorings, a nicotine solution, a monoglyceride, and a sweetener (acesulfame K).
Two NRT products were tested, Nicorette Peppermint 2 mg lozenge, and Nicotinell Licorice 2 mg gum. The products weigh 0.6 g and 1.2 g per unit of use, respectively. The lozenge contains nicotine in the form of resinate, fillers (mannitol, xanthan gum, gum arabic, magnesium stearate, hypromellose, titanium dioxide, microcrystalline cellulose, potassium silicate, polysorbate 80), pH adjuster (sodium carbonate), sweetener (sucralose, acesulfame K) and flavorings. The gum contains nicotine polacrilex, chewing gum base, sweetener (acesulfame K, saccharin, sodium saccharin, sorbitol, xylitol, mannitol), pH adjusters (calcium carbonate, sodium carbonate, sodium bicarbonate), flavoring, glycerol, gelatine, titanium dioxide, canauba wax and talcum powder.
The tested snus product was General® Portion Original Large which is one of the eight products for which FDA-CTP issued a MRTP order in 2019. General has a moisture content of 51% and comes in a rectangular pouch made of non-woven material. The pouch measures 18 × 33 mm and weighs 1.0 g. The pouch contains ground, air-cured tobacco, water, sodium chloride, sodium carbonate, humidifying agents, and food-grade flavorings. During manufacturing, the mixture of ground tobacco, water and salt is heat treated (pasteurized) to reduce microbial activity.
Two variants of moist snuff were tested: the Cooperation Centre for Scientific Research Relative to Tobacco (CORESTA) Smokeless Tobacco Reference Product (CRP2.1)  which is a non-pouched product with a 53% moisture content. It contains both air-cured and dark fire-cured tobaccos, water, sodium chloride, burley stem, and sodium carbonate. We also tested one of the market-leading pouched products in the U.S., Grizzly Pouches Wintergreen. It has a moisture content of 52%, comes in a 18 × 44 mm pouch made of a non-woven material, and weighs 1.3 g.
The manufacturing processes for both moist snuff products include fermentation of the tobacco.
A total of 43 compounds were selected for analysis, 36 of which are classified as HPHCs by the FDA . This included the nine compounds on the FDA-CTP’s list of HPHCs relevant for smokeless tobacco products: acetaldehyde, arsenic, B(a)P, cadmium, crotonaldehyde, formaldehyde, nicotine (total and unprotonated), NNK, and NNN . We also screened for some other compounds covered by the GOTHIATEK standard (aflatoxin B2, G1 and G2, nitrite, and ochratoxin A) . In addition, N-nitrosoanatabine (NAT), and N-nitrosoanabasine (NAB) were included to cover all four, primary TSNAs. All reported results are based on wet weight.
GOTHIATEK also includes maximum levels for a large number of agrochemicals. Analyses of such compounds were considered beyond the scope of the current study.
Sample handling and analysis
The snus product and the two ZYN products were obtained from Swedish Match Distribution Center, Stockholm, Sweden. The NRT products were obtained from on-line pharmacies in Sweden. CRP2.1 was obtained from North Carolina State University Tobacco Analytical Services Laboratory, North Carolina, U.S. The pouched moist snuff product was purchased from Hardec’s Wholesale, Kentucky, U.S. One batch of each product was analyzed. All analyses were performed within 3 weeks of obtaining the product. Pending analysis, the NRTs and ZYN dry were stored at room temperature whereas ZYN moist, snus and the moist snuff products were kept refrigerated or frozen. Where applicable, we followed the CORESTA Guide No. 11 Technical Guide for Sample Handling of Smokeless Tobacco and Smokeless Tobacco Products .
Table 2 lists the tested compounds and provides brief descriptions of the analytical methods. The analyses were performed in triplicate on the entire product including the pouch material, where applicable. The data are presented as the mean and standard deviation of the triplicate (Tables 3–6). Where one or two out of the three replicates have no measurable levels i.e., below limit of quantification (LoQ), the values for the individual replicates were set to 50% of the LoQ for the mean and standard-deviation calculations. Most of the included compounds were analyzed at the external contract laboratory Eurofins, Lidköping, Sweden. Polonium-210 was analyzed at Labstat, Kitchener, Canada. A few compounds that could not be analyzed at Eurofins were analyzed in-house at the Swedish Match Laboratory, Stockholm, Sweden. All methods used by Eurofins and Swedish Match are validated and accredited to ISO 17025 for tobacco products and nicotine pouches. For NRT-matrices, the analytical methods are validated and fit for its intended purpose, but not yet accredited according to ISO 17025. All three laboratories are accredited according to ISO 17025.
Using CORESTA Recommended Method No. 69 we measured pH to permit estimates of the amount of unprotonated nicotine.
In total, we analyzed 43 compounds (including nicotine). Table 3 shows the analytical results for nitrosamines, Table 4 for PAHs, Table 5 for heavy metals and radionuclides, and Table 6 for the remaining compounds.
As expected, total and unprotonated “free” nicotine at varying levels was quantified in all tested products (Table 6).
In the two types of ZYN nicotine pouches, 38 of the 43 analyzed compounds were below the respective level of quantification. Most notably, this included all tested nitrosamines and PAHs. In addition to nicotine, a total of three HPHCs were found in both the ZYN dry and ZYN moist products: formaldehyde (10.3 µg/g and 1.5 µg/g, respectively), chromium (0.160 µg/g and 0.099 µg/g, respectively), and ammonia (62 µg/g and 66 µg/g, respectively). Traces of nickel, just above the quantification limit, were found in ZYN dry (0.067 µg/g).
In addition to nicotine, nickel at a low level (0.086 µg/g) was the only compound found in the NRT lozenge product. In the NRT gum product eight compounds in addition to nicotine were quantified. This included cadmium (0.043 µg/g), chromium (0.850 µg/g), lead (0.067 µg/g), nickel (0.243 µg/g), acetaldehyde (4.7 µg/g), ammonia (4.5 µg/g), and the uranium isotopes 235U (0.14 Bq/kg) and 238U (2.76 Bq/kg). Notably, no nitrosamines or PAHs were found in either NRT product.
All compounds quantified in the ZYN products were also found in snus and the moist snuff products, but the levels found were vastly different. In general, the ZYN and NRT products contained the lowest levels followed by snus and moist snuff. Compared to snus, 69% and 81% less chromium were found in ZYN dry and ZYN moist, respectively. ZYN dry contained 92% less nickel than snus. For ammonia, 93% and 92% less were found in ZYN dry and ZYN moist, respectively. ZYN moist and snus contained comparable levels of formaldehyde whereas the level in ZYN dry were about 5 times higher than in snus.
Where lead, cadmium, nickel, and ammonia were quantified in the NRT products, their levels were 63–99% lower compared to snus. In contrast, 63% more chromium were found in the NRT gum than snus. The NRT gum contained half as much of acetaldehyde compared to snus. Also, the two uranium isotopes were only found in the NRT gum.
The snus product contained 19 of the 43 compounds. In addition to nicotine, this included five nitrosamines (NAB, NAT, NDMA, NNK, and NNN), six heavy metals (arsenic, cadmium, chromium, lead, nickel, selenium), acetaldehyde, ammonia, anabasine, formaldehyde, nornicotine, ochratoxin A, and a polonium isotope (210Po).
A total of 27 and 26 compounds were quantified in the loose and pouched moist snuff products, respectively. Apart from nicotine, this included six nitrosamines (NAB, NAT, NDMA, NNN, NNK, and N-nitrososarcosine (NSAR)) in both products and N-Nitrosopyrrolidine (NPYR) in the loose moist snuff. The levels of NNN and NNK were about five to 12-fold higher than in the snus product. A total of six and five PAHs were quantified in the loose and pouched moist snuff products, respectively. The quantified heavy metals were the same, and at comparable levels as those found in snus: arsenic, cadmium, chromium, lead, nickel, and selenium. Other compounds present in the moist snuff products were acetaldehyde, ammonia, anabasine, coumarin, formaldehyde, nornicotine, and 210Po. In addition, the pouched moist snuff product contained ochratoxin A.
Tobacco harm reduction is defined as “decreasing total morbidity and mortality, without completely eliminating tobacco and nicotine use” . In practice, a prerequisite for tobacco harm reduction is therefore availability of nicotine products which entail lower risks than cigarettes. The MRTP order for Swedish snus issued by the FDA-CTP in 2019 authorized the following statement to be used for marketing purposes: “Using General snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis”. This list of “tobacco-related” adverse health outcomes thus includes the conditions that contribute the most to the excess morbidity and mortality documented among cigarette smokers . However, some compounds are naturally present in tobacco, formed during curing, or snus production. This includes nitrosamines that have been classified as potentially carcinogenic. From that perspective a tobacco-free nicotine pouch should, at least in theory, represent an improvement in terms of exposure to nitrosamines and other tobacco-related compounds.
This paper reports the results from a screening of 43 compounds in two types of ZYN products, as one of the crucial initial steps in a full risk assessment. For comparative purposes the same screening was performed in some other oral, nicotine delivery products: Swedish snus, moist snuff, an NRT lozenge and an NRT gum.
The fewest compounds (nicotine included) were quantified in the NRT lozenge (two), followed by the ZYN moist and ZYN dry products (four and five, respectively), and the NRT gum (nine). Notably, we found no measurable levels of nitrosamines or PAHs in any of these products.
In the snus product we quantified 19 compounds, including NNN and NNK but no PAHs. In contrast, the two loose and pouched moist snuff products contained 27 and 26 compounds, respectively. These included several PAHs, presumably originating from the dark fire-cured tobacco. The NNN and NNK levels in the moist snuff products were five- to 12-fold higher than in the snus product. The substantial differences between snus and moist snuff may be explained by differences in the selection of raw tobaccos (fire-cured tobacco is not used in snus production) as well as different manufacturing processes: snus is heat treated so that the finished product has a very low microbial activity, whereas moist snuff is fermented [2, 14]. Fermentation may allow for bacterial production of nitrosamines.
Few HPHCs were found and at low levels in ZYN dry and ZYN moist suggesting that the products have a low toxicity. Consistent with our findings in vitro toxicology studies showed that nicotine pouches are associated with less cytotoxicity and has less impact on biological processes compared to conventional smokeless tobacco products [17,18,19]. Furthermore, extracts from nicotine pouches were not mutagenic nor genotoxic . The fact that use of conventional, smokeless tobacco products typically entails simultaneous exposure to a larger number and broader variety of HPHCs than is the case with nicotine pouches may help to explain these findings.
We found considerable variations in total as well as unprotonated, “free nicotine” among the tested products. “Free nicotine” has been suggested to more accurately than total nicotine reflect the potential for nicotine uptake with oral, nicotine delivery products . However, it may not be an ideal proxy for the total uptake among consumers as the concept of “free nicotine” does not consider the amount of nicotine that is extracted from the product. Reliable assessments of the nicotine pharmacokinetics of individual products therefore require clinical studies that directly measure the uptake of nicotine.
Clinical data on the nicotine pharmacology of ZYN dry showed a similar nicotine-delivery profile and comparable nicotine exposure to that with snus and moist snuff . In contrast, nicotine pouches were associated with less positive subjective effects and slower nicotine delivery when compared to combustible cigarettes. This suggests that nicotine pouches might have a lower abuse liability [22, 23].
A similar study reported by Azzopardi and colleagues  analyzed 26 compounds in a range of nicotine delivery products including a nicotine pouch (LYFT®), Swedish-type snus, moist snuff, and NRTs (lozenge and gum). Our results confirm this study as no TSNAs, or B(a)P could be quantified in ZYN or NRT products and extend findings to include more HPHCs from the compound classes nitrosamines, PAHs, metals, and radionuclides.
The data presented here is limited to the HPHC content of nicotine pouches in relation to other smokeless nicotine/tobacco products. Although such data may suggest the potential for adverse health effects among individual consumers, a full risk assessment requires more data. Recent in vitro studies [17,18,19] and clinical studies [21, 25,26,27,28,29] have provided important insights. However, long-term data on consumer perceptions and behaviors and most importantly epidemiological data are needed for a full risk assessment.
A screening for 43 HPHCs in two variants of the nicotine pouch product ZYN showed that only few HPHCs were quantified and all at consistently low levels. These findings were similar to those for the tested NRT products. Notably, nitrosamines or PAHs were not found in either the ZYN or NRT products.
Availability of data and materials
All datasets used are available upon reasonable request to the corresponding author. For more details regarding analysis methods please contact the respective lab.
Cooperation Centre for Scientific Research Relative to Tobacco
CORESTA Smokeless Tobacco Reference Product
The Center for Tobacco Products at the United States’ Food and Drug Administration
Gas chromatography-mass spectrometry
Harmful and potentially harmful constituents
High performance liquid chromatography with fluorescence detection
High-performance liquid chromatography with tandem mass-spectrometry
Inductively coupled plasma-mass-spectrometry
Limit of Quantification
Modified risk tobacco product
Nicotine replacement therapy products
Polycyclic aromatic hydrocarbons
Ultra-performance liquid chromatography with tandem mass spectrometry
The World Health Organization
Lee PN. Epidemiological evidence relating snus to health–an updated review based on recent publications. Harm Reduct J. 2013;10:36.
Rutqvist LE, Curvall M, Hassler T, Ringberger T, Wahlberg I. Swedish snus and the GothiaTek® standard. Harm Reduct J. 2011;8:11.
Statistics Sweden. Tobaksvanor efter indikator, redovisningsgrupp och kön. Andelar i procent och skattat antal i tusental. År 2008–2009–2018–2019 2019 http://www.statistikdatabasen.scb.se/pxweb/sv/ssd/START__LE__LE0101__LE0101H/LE01012019H06/. Accessed 7 Apr 2021.
The World Health Organization. WHO Global Report: Mortality Attributable to Tobacco 2012 http://apps.who.int/iris/bitstream/handle/10665/44815/9789241564434_eng.pdf. Accessed 3 June 2021.
U.S. Food & Drug Administration. Modified Risk Tobacco Products 2021 https://www.fda.gov/tobacco-products/advertising-and-promotion/modified-risk-tobacco-products. Accessed 31 Mar 2021.
U.S. Food & Drug Administration. Scientific Review of Modified Risk Tobacco Product Application (MRTPA) Under Section 911 (d) of the FD&C Act – Technical Project Lead 2014 https://www.fda.gov/media/131923/download. Accessed 3 June 2021.
Swedish Match AB. GOTHIATEK® limits for undesired components 2021 https://www.swedishmatch.com/Snus-and-health/GOTHIATEK/GOTHIATEK-standard/. Accessed 31 Mar 2021.
Lawler TS, Stanfill SB, Tran HT, Lee GE, Chen PX, Kimbrell JB, et al. Chemical analysis of snus products from the United States and northern Europe. PLoS ONE. 2020;15(1): e0227837.
Richter P, Hodge K, Stanfill S, Zhang L, Watson C. Surveillance of moist snuff: total nicotine, moisture, pH, un-ionized nicotine, and tobacco-specific nitrosamines. Nicotine Tob Res. 2008;10(11):1645–52.
Delnevo CD, Hrywna M, Miller Lo EJ, Wackowski OA. Examining market trends in smokeless tobacco sales in the United States: 2011–2019. Nicotine Tob Res. 2020. https://doi.org/10.1093/ntr/ntaa239.
Cooperation Centre for Scientific Research Relative to Tobacco. CORESTA Smokeless Tobacco Reference Product CRP2.1—Moist Snuff 2016 https://www.coresta.org/sites/default/files/pages/2016_CRP2.1.pdf. Accessed 31 Mar 2021.
U.S. Food & Drug Administration. Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke: Established List 2012 https://www.federalregister.gov/documents/2012/04/03/2012-7727/harmful-and-potentially-harmful-constituents-in-tobacco-products-and-tobacco-smoke-established-list. Accessed 31 Mar 2021.
U.S. Food & Drug Administration. Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act 2012 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-harmful-and-potentially-harmful-constituents-tobacco-products-and-tobacco-smoke-under. Accessed 2 June 2021.
Cooperation Centre for Scientific Research Relative to Tobacco. CORESTA Guide N° 11: Technical Guide for Sample Handling of Smokeless Tobacco and Smokeless Tobacco Products 2020 https://www.coresta.org/sites/default/files/technical_documents/main/Guide-No11-Smokeless-Sample-Handling_May20.pdf. Accessed 2 June 2021.
Institute of Medicine. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington, DC: The National Academies Press; 2001.
U.S. Food & Drug Administration. FDA grants first-ever modified risk orders to eight smokeless tobacco products 2019 https://www.fda.gov/news-events/press-announcements/fda-grants-first-ever-modified-risk-orders-eight-smokeless-tobacco-products. Accessed 2 June 2021.
Bishop E, East N, Bozhilova S, Santopietro S, Smart D, Taylor M, et al. An approach for the extract generation and toxicological assessment of tobacco-free ‘modern’ oral nicotine pouches. Food Chem Toxicol. 2020;145: 111713.
East N, Bishop E, Breheny D, Gaca M, Thorne D. A screening approach for the evaluation of tobacco-free “modern oral” nicotine products using real time cell analysis. Toxicol Rep. 2021;8:481–8.
Yu F, Rudd K, Pour SJ, Trelles Sticken E, Dethloff O, Wieczorek R, et al. Preclinical assessment of tobacco-free nicotine pouches demonstrates reduced in vitro toxicity compared with tobacco snus and combustible cigarette smoke. Appl Vitro Toxicol. 2022. https://doi.org/10.1089/aivt.2021.0020.
Henningfield JE, Radzius A, Cone EJ. Estimation of available nicotine content of six smokeless tobacco products. Tob Control. 1995;4:57–61.
Lunell E, Fagerström K, Hughes J, Pendrill R. Pharmacokinetic comparison of a novel non-tobacco-based nicotine pouch (ZYN) with conventional, tobacco-based swedish snus and american moist snuff. Nicotine Tob Res. 2020;22(10):1757–63.
Rensch J, Liu J, Wang J, Vansickel A, Edmiston J, Sarkar M. Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes. Psychopharmacology. 2021. https://doi.org/10.1007/s00213-021-05948-y.
McEwan M, Azzopardi D, Gale N, Camacho OM, Hardie G, Fearon IM, et al. A randomised study to investigate the nicotine pharmacokinetics of oral nicotine pouches and a combustible cigarette. Eur J Drug Metab Pharmacokinet. 2021. https://doi.org/10.1007/s13318-021-00742-9.
Azzopardi D, Liu C, Murphy J. Chemical characterization of tobacco-free “modern” oral nicotine pouches and their position on the toxicant and risk continuums. Drug Chem Toxicol. 2021. https://doi.org/10.1080/01480545.2021.1925691.
Liu J, Rensch J, Wang J, Jin X, Vansickel A, Edmiston J, et al. Nicotine pharmacokinetics and subjective responses after using nicotine pouches with different nicotine levels compared to combustible cigarettes and moist smokeless tobacco in adult tobacco users. Psychopharmacology. 2022;239(9):2863–73.
Rensch J, Liu J, Wang J, Vansickel A, Edmiston J, Sarkar M. Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes. Psychopharmacology. 2021;238:3325–34.
Azzopardi D, Haswell LE, Frosina J, McEwan M, Gale N, Thissen J, et al. Assessment of biomarkers of exposure and potential harm, and physiological and subjective health measures in exclusive users of nicotine pouches and current, former and never smokers. Biomarkers. 2022. https://doi.org/10.1080/1354750X.2022.2148747.
McEwan M, Azzopardi D, Gale N, Camacho OM, Hardie G, Fearon IM, et al. A randomised study to investigate the nicotine pharmacokinetics of oral nicotine pouches and a combustible cigarette. Eur J Drug Metab Pharmacokinet. 2021;47:211–21.
Chapman F, McDermott S, Rudd K, Taverner V, Stevenson M, Chaudhary N, et al. A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobacco-free oral nicotine pouches relative to cigarettes. Psychopharmacology. 2022;239(9):2931–43.
Joo KM, Shin MS, Jung JH, Kim BM, Lee JW, Jeong HJ, et al. Determination of N-nitrosodiethanolamine, NDELA in cosmetic ingredients and products by mixed mode solid phase extraction and UPLC-tandem mass spectrometry with porous graphitic carbon column through systemic sample pre-cleanup procedure. Talanta. 2015;137:109–19.
Miralles P, Chisvert A, Salvador A. Determination of N-nitrosamines in cosmetic products by vortex-assisted reversed-phase dispersive liquid–liquid microextraction and liquid chromatography with mass spectrometry. J Sep Sci. 2018;41(15):3143–51.
Herrmann SS, Duedahl-Olesen L, Granby K. Simultaneous determination of volatile and non-volatile nitrosamines in processed meat products by liquid chromatography tandem mass spectrometry using atmospheric pressure chemical ionisation and electrospray ionisation. J Chromatography A. 2014;1330:20–9.
Cooperation Centre for Scientific Research Relative to Tobacco. CORESTA Recommended Method No. 86: Determination of Select Carbonyls in Tobacco and Tobacco Products by UHPLC-MS/MS 2018 https://www.coresta.org/sites/default/files/technical_documents/main/CRM_86-Jan2018.pdf. Accessed 2 June 2021.
Cooperation Centre for Scientific Research Relative to Tobacco. CORESTA Recommended Method No. 62: Determination of Nicotine in Tobacco and Tobacco Products by Gas Chromatographic Analysis 2020 https://www.coresta.org/sites/default/files/technical_documents/main/CRM_62-April2020.pdf. Accessed 2 June 2021.
Cooperation Centre for Scientific Research Relative to Tobacco. CORESTA Recommended Method No. 69: determination of pH of Tobacco and Tobacco Products 2017 https://www.coresta.org/sites/default/files/technical_documents/main/CRM_69-July2017.pdf. Accessed 2 June 2021.
Centers for Disease Control and Prevention. Revised Protocol for Analysis of Nicotine, Total Moisture, and pH in Smokeless Tobacco Products. Federal Register. 2009;73(121):402.
The authors wish to thank Mikael Staaf, Camilla Pramfalk, Robert Pendrill and Tryggve Ljung for reviewing the manuscript.
The study was funded by Swedish Match AB, who markets the ZYN and General products described in the article. The funder designed the study, the analyses and collection of data were mainly (if possible) carried out at external laboratories. The funder interpreted the data and wrote the manuscript.
Ethics approval and consent to participate
Consent for publication
All authors are either employees of or otherwise funded by Swedish Match AB.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Back, S., Masser, A.E., Rutqvist, L.E. et al. Harmful and potentially harmful constituents (HPHCs) in two novel nicotine pouch products in comparison with regular smokeless tobacco products and pharmaceutical nicotine replacement therapy products (NRTs). BMC Chemistry 17, 9 (2023). https://doi.org/10.1186/s13065-023-00918-1
- Tobacco harm reduction
- Oral tobacco
- Swedish snus
- Nicotine pouch
- Nicotine replacement therapy (NRT)
- Moist snuff
- Chemical analysis
- Harmful and potentially harmful constituents (HPHC)
- Oral tobacco derived nicotine (OTDN) pouches